Skip to main content
SpringerLink
Log in

Reduction of the local toxicity of intraperitoneal chemotherapy; an experimental model

  • Published:
Irish Journal of Medical Science Aims and scope Submit manuscript

Summary

Intraperitoneal (I.P.) administration of chemotherapeutic agents, in particular, cisplatin and bleomycin is successfully used in the treatment of ovarian1–5 and gastrointestinal malignancies6–7. Their use however, is limited by the rapid development of adhesions8–9. The vinca alkaloid group of chemotherapeutic agents has been shown to impair the acute inflammatory reaction10, which plays an important role in adhesion formation, thereby providing the rationale for addition of vindesine to an I.P. regimen containing cisplatin and bleomycin. A rat model was used to study the effects of various I.P. chemotherapeutic regimens on adhesion formation. Four groups were studied (30 rats/ Group). Regimens used included Group A (Saline), Group B (Vindesine 0.1 mg/ kg), Group C (Cisplatin 5 mg/kg and Bleomycin 0.2 mg/kg), and Group D (Cisplatin 5 mg/kg, Bleomycin 0.2 mg/ kg and Vindesine 0.1 mg/kg). In order to grade adhesion formation, animals were sacrificed on days 2, 14 and 28, with the severity of adhesions graded on a scale of I–IV in order of increasing severity. Adhesion formation in Group A (Saline) and Group B (Vindesine) was similar. The addition of Vindesine to Group C (Cisplatin and Bleomycin) resulted in a significant reduction in adhesion formation (p<0.01). The results of this experimental study suggest that the local toxicity of I.P. chemotherapy may be reduced by the inclusion of a vinca alkaloid

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Markman, M. Intraperitoneal chemotherapy for malignant diseases of the gastrointestinal tract Surg. Gynae. Obs. 1987: 164, 89–93

    CAS  Google Scholar 

  2. Howell, S. B., Pfeifle, C. E., Wung, W. C. et al. Intraperitoneal cisplatin with systemic thiosulphate protection. Ann. Intern. Med. 1982: 97, 845–851.

    PubMed  CAS  Google Scholar 

  3. Markman, M., Howell, S. B., Pfeifle, C. E. et al. Intraperitoneal chemotherapy with high dose cisplatin and cytarabine in patients with refractory ovarian carcinoma and other malignancies confined to the abdominal cavity. Proc. Am. Soc. Clin. Oncol. 1984: 3, 165.

    Google Scholar 

  4. Markman, M., Green, M.R., Pfeifle, C. E. et al. Combination interactivity chemotherapy in patients with stage III-IV ovarian carcinoma failing standard regimens (abstr). Proc. Am. Soc. Clin. Oncol. 1983: 2, 147.

    Google Scholar 

  5. Lucas, W. E., Markman, M., Howell, S. B. Intraperitoneal chemotherapy for advanced ovarian carcinoma. Am. J. Obs. Gynae. 1985: 152, 474–478.

    CAS  Google Scholar 

  6. Cuncliffe, W. J., Sugarbaker, P. H. Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy. Br. J. Surg. 1989: 76, 1082–1090.

    Article  Google Scholar 

  7. Gianola, F. J., Sugarbaker, P. H., Barofsky, I. et al. Toxicity studies of adjuvent intravenous versus intraperitoneal 5-FU in patients with advanced primary colon or rectal cancer. Am. J. Clin. Oncol. 1986: 9, 403–10.

    Article  PubMed  CAS  Google Scholar 

  8. Markman, M., Cleary, S., Howell, S. B., Lucas, W. E. Complications of extensive adhesion formation after intraperitoneal chemotherapy. Surg. Gynae. Obs. 1986: 162, 445–448.

    CAS  Google Scholar 

  9. Litterest, C. L., Collins, J. M., Lowe, M. C., Arnold, S. T. et al. Local and systemic toxicity from large-volume intraperitoneal administration of doxorubicin in the rat Cancer Treat. Rep. 1982: 66, 157–161.

    Article  Google Scholar 

  10. Cohen, S. C., Gabelnick, H. L., Johnson, R. K., Goldin, A. Effects of antineoplastic agents on wound healing in mice. Surg. 1975: 78, 238–244.

    CAS  Google Scholar 

  11. Markman, M., Cleary, S., Lucas, W., Weiss, R., Howell, S. B. Intraperitoneal chemotherapy employing a regimen of cisplatin, cytarabine, and bleomycin. Cancer Treat. Rep. 1986: 70, 755–760.

    PubMed  CAS  Google Scholar 

  12. Young, R. C., Chabner, B. A., Hubbard, S. P. et al. Advanced ovarian adenocarcinoma: a prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N. Eng. J. Med. 1978: 299, 1261–1266.

    CAS  Google Scholar 

  13. Israel, A. et al. Treatment of advanced epithelial ovarian cancer with a Ci-dichloro-diamine platinum, cyclophosphamide, and bleomycin combination. Am. J. Clin. Oncol. 1988: 11, 7–11.

    PubMed  CAS  Google Scholar 

  14. Unpublished data.

  15. Dendrick, R. L., Meyers, C. E., Bungay, P. M., De Vita, V. T. Pharmokinetic rationale for peritoneal drug administration in the treatment of ovarian carcinoma. Cancer Treat. Rep. 1978: 62, 1–11.

    Google Scholar 

  16. Jones, R. B., Myers, C. E., Guarino, A. M. et al. High volume intraperitoneal chemotherapy (belly bath) for ovarian cancer. Cancer, Chemother. Pharmacol. 1978: 1, 161–166.

    Article  CAS  Google Scholar 

  17. Kaplan, R. A., Markman, M., Lucas, W. E., Pfeifle, C., Howell, S. B. Infectious peritonitis in patients receiving intraperitoneal chemotherapy. Amer. J. Med. 1985: 78, 49–53.

    Article  PubMed  CAS  Google Scholar 

  18. Ozols, R. F., Young, R. C., Speyer, J. L. et al. Phase 1 and pharmacologic studies of adriamycin administered intraperitoneally to patients with ovarian carcinoma. Cancer Research 1982: 42, 4265–9.

    PubMed  CAS  Google Scholar 

  19. Bradley, J. A., McWhinnie, D. L., Hamilton, M. D. et al. Sclerosing obstructive peritonitis after continuous ambulatory peritoneal dialysis. Lancet 1983: 2, 113–114.

    Article  PubMed  CAS  Google Scholar 

  20. Levinson, C. J., Swolin, K. Postoperative adhesions: etiology, prevention, and therapy. Clin. Obstet Gynae. 1980: 23, 1213–1220.

    Article  CAS  Google Scholar 

  21. Raftery, A.T. Effect of peritoneal trauma on peritoneal fibrinloytic activity and intraperitoneal adhesion formation. Eur. Surg. Res. 1981: 13, 397–401.

    Article  PubMed  CAS  Google Scholar 

  22. Buckman, R. F., Woods, M., Sargent, L., Gervin, A. A unifying pathogenic mechanism in the etiology of intraperitoneal adhesions. J. Surg. Research 1976: 20, 1–5.

    Article  CAS  Google Scholar 

  23. Thompson, J. N., Paterson-Brown, S., Harboume, T., Whawell, S. A., Kalodiki, E., Dudley, H. A. F. Reduced human peritoneal plasminogen activating activity: possible mechanism of adhesion formation. Br. J. Surg. 1989: 76, 382–384.

    Article  PubMed  CAS  Google Scholar 

  24. Gunderson, S. Dacarbazine, Vindesine and Cisplatin combination chemotherapy in advanced malignant melanoma; a phase II study. Cancer Treat. Rep. 1987: 71, 997–9.

    Google Scholar 

  25. Postmus, P. E. et al. Cisplatin and Vindesine, a phase II study in lung cancer. J. Cancer Res. Clin. Oncol. 1987: 113, 99–100.

    Article  PubMed  CAS  Google Scholar 

  26. Kuhbock, J. et al. Palliative and adjuvant chemotherapy of metastatic renal cancer. Semin Surg. Oncol. 1988: 4, 116–23.

    PubMed  CAS  Google Scholar 

  27. Rhomberg, W. U. Vindesine for recurrent and metastatic cancer of the uterine cervix: a phase II trial. Cancer Treat. Rep. 1986: 70, 1455–1457.

    PubMed  CAS  Google Scholar 

  28. Willemse, P. H. et al. Long tern suurvival after vinblastine, bleomycin and cisplatin treatment in patients with germ cell tumours of the ovary; an update. Gynaecol. Oncol. 1987: 28, 268–277.

    Article  CAS  Google Scholar 

  29. Hill, B. T., Whelan, D. H. Comparative effects of vincristine and vindesine on cell cycle kinetics in vitro. Cancer Treat. Rev. 1980: 7 (Supplement), 5–15.

    Article  PubMed  Google Scholar 

  30. Argenta, L. C., Manders, E. K. Mitomycin C extravasation injuries. Cancer 1983: 51, 1082–2.

    Article  Google Scholar 

  31. Surwit, E. A. etal. Phase II trial of Vinblastine in previously treated patients with ovarian cancer, a Southwest Oncology Group Study. Gynaecol. Oncol. 1987: 28, 14–19.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Department of Surgery, and Regional Hospital, Cork

    R. G. Molloy, B. Crowley, K. T. Moran & M. P. Brady

Authors
  1. R. G. Molloy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Crowley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K. T. Moran
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. P. Brady
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molloy, R.G., Crowley, B., Moran, K.T. et al. Reduction of the local toxicity of intraperitoneal chemotherapy; an experimental model. I.J.M.S. 159, 175–177 (1990). https://doi.org/10.1007/BF02937237

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02937237

Keywords

Search

Navigation